COMMUNIQUÉS West-GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
07/08/2025
BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN FRANCISCO [...]
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
07/08/2025
Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98% Sustained [...]
INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes
07/08/2025
Company to Host Conference Call Today, August 7th, at 4:30pm ET BOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on [...]
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
07/08/2025
Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in [...]
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
07/08/2025
-- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance ; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into [...]
Apyx Medical Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07/08/2025
CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”) today announced that on August 4, 2025, Apyx granted a nonstatuatory stock option to purchase [...]
Biodesix Announces Second Quarter 2025 Results and Highlights
07/08/2025
Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference [...]
TerrAscend Reports Second Quarter 2025 Financial Results
07/08/2025
Net Revenue totaled $65 million and Gross Profit Margin was 51.1% from continuing operations, excluding Michigan 12 th consecutive quarter of positive Cash Flow from continuing operations and 8 th consecutive quarter of [...]
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
07/08/2025
- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose expansions on track [...]
AMN Healthcare Announces Second Quarter 2025 Results
07/08/2025
Quarterly revenue of $658 million and Adjusted EBITDA of $58.3 million; GAAP loss of ($3.02) /share and adjusted EPS of $0.30 DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the [...]
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference
07/08/2025
DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will [...]
Globus Medical Reports Second Quarter 2025 Results
07/08/2025
AUDUBON, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025. Worldwide net [...]
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates
07/08/2025
WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and [...]
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
07/08/2025
New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning Vonaprument Selected by EMA as One of ~20 PRIME Development [...]
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
07/08/2025
Recent positive recommendation by the Independent Data Monitoring Committee (“IDMC”) to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven final [...]
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
07/08/2025
– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and dual-payload ADCs [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/08/2025
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) NEW YORK, 07 août 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth Code ISIN : FR0010425595 Date Nombre total d’actions composant le [...]
Monthly information on share capital and company voting rights
07/08/2025
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
07/08/2025
– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 [...]

Pages